Seeking Alpha

CombiMatrix's (CBMX) decision to shift its focus to prenatal testing and away from oncology...

CombiMatrix's (CBMX) decision to shift its focus to prenatal testing and away from oncology looks to be bearing fruit, with the company saying that it achieved preliminary annual growth rates of 172% in Q4 and 171% in the full year for prenatal diagnoses. Overall testing grew 21% and 25% respectively. Shares sky 21%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs